Validation of Calculated Globulin (CG) as a Screening Test for Antibody Deficiency in an Italian University Hospital
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.org..
BACKGROUND: Morbidity and mortality of primary and secondary antibody deficiencies (AD) are frequently associated with diagnostic delays. These could be avoided by a combination of factors including a widespread and effective development in screening tests.
METHODS: Calculated globulin (CG), derived from the difference between serum total protein and albumin levels, reflects immunoglobulin serum levels and has shown to have a predictive value in the early diagnosis of antibody deficiencies. This study investigated the possibility to use low levels of CG to detect antibody deficiency in an Italian University Hospital.
RESULTS: First, we conducted an analysis of anonymized adult samples collected at our biochemistry laboratory with a range of calculated globulin levels from 15 to 22 g/l. A CG cut-off of 19 g/l detected subjects with IgG lower than 600 mg/dl with a sensitivity of 70% and a specificity of 75%. To further verify the clinical usefulness of CG, we retrospectively evaluated the relationship between CG values and serum IgG levels in 38 patients diagnosed with CVID at our Institution. Using a CG cut-off of 19 g/l, we detected antibody deficiency in 97.3% (37/38) of the subjects present in our cohort.
CONCLUSION: Finally, we chose a CG value of 19 g/l as the cut-off for a prospective AD screening program. The results of this study show that a screening CG test can be used as a tool to reduce diagnostic delays, improve long-term prognosis and reduce the healthcare costs of antibody deficiency.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Current pharmaceutical biotechnology - 19(2018), 9 vom: 01., Seite 728-733 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pecoraro, Antonio [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AD screening |
|---|
| Anmerkungen: |
Date Completed 06.02.2019 Date Revised 15.02.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1389201019666180808163311 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM287305562 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM287305562 | ||
| 003 | DE-627 | ||
| 005 | 20231225053720.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1389201019666180808163311 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0957.xml |
| 035 | |a (DE-627)NLM287305562 | ||
| 035 | |a (NLM)30091407 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pecoraro, Antonio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Validation of Calculated Globulin (CG) as a Screening Test for Antibody Deficiency in an Italian University Hospital |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.02.2019 | ||
| 500 | |a Date Revised 15.02.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.org. | ||
| 520 | |a BACKGROUND: Morbidity and mortality of primary and secondary antibody deficiencies (AD) are frequently associated with diagnostic delays. These could be avoided by a combination of factors including a widespread and effective development in screening tests | ||
| 520 | |a METHODS: Calculated globulin (CG), derived from the difference between serum total protein and albumin levels, reflects immunoglobulin serum levels and has shown to have a predictive value in the early diagnosis of antibody deficiencies. This study investigated the possibility to use low levels of CG to detect antibody deficiency in an Italian University Hospital | ||
| 520 | |a RESULTS: First, we conducted an analysis of anonymized adult samples collected at our biochemistry laboratory with a range of calculated globulin levels from 15 to 22 g/l. A CG cut-off of 19 g/l detected subjects with IgG lower than 600 mg/dl with a sensitivity of 70% and a specificity of 75%. To further verify the clinical usefulness of CG, we retrospectively evaluated the relationship between CG values and serum IgG levels in 38 patients diagnosed with CVID at our Institution. Using a CG cut-off of 19 g/l, we detected antibody deficiency in 97.3% (37/38) of the subjects present in our cohort | ||
| 520 | |a CONCLUSION: Finally, we chose a CG value of 19 g/l as the cut-off for a prospective AD screening program. The results of this study show that a screening CG test can be used as a tool to reduce diagnostic delays, improve long-term prognosis and reduce the healthcare costs of antibody deficiency | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AD screening | |
| 650 | 4 | |a calculated globulin (CG) | |
| 650 | 4 | |a common variable immunodeficiency (CVID) | |
| 650 | 4 | |a primary antibody deficiency (PAD) | |
| 650 | 4 | |a secondary antibody deficiency(SAD). | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Serum Globulins |2 NLM | |
| 700 | 1 | |a Jolles, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Crescenzi, Ludovica |e verfasserin |4 aut | |
| 700 | 1 | |a Varricchi, Gilda |e verfasserin |4 aut | |
| 700 | 1 | |a Marone, Giancarlo |e verfasserin |4 aut | |
| 700 | 1 | |a Savoia, Marcella |e verfasserin |4 aut | |
| 700 | 1 | |a Genovese, Arturo |e verfasserin |4 aut | |
| 700 | 1 | |a Spadaro, Giuseppe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical biotechnology |d 2000 |g 19(2018), 9 vom: 01., Seite 728-733 |w (DE-627)NLM11369072X |x 1873-4316 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2018 |g number:9 |g day:01 |g pages:728-733 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1389201019666180808163311 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2018 |e 9 |b 01 |h 728-733 | ||